Chemistry:IMAB362
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Target | CLDN18.2 |
| Clinical data | |
| Other names | claudiximab |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| ChemSpider |
|
  (what is this?) (verify) | |
IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is under investigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.[1]
The drug is in phase II clinical trials (As of January 2013).[2]
Preliminary results from the phase II 'FAST' trial in June 2016 suggest it is helpful for advanced gastric cancer (and a phase III trial will be planned).[3]
References
- ↑ "Our mission - Ganymed Pharmaceuticals GmbH - Ganymed Pharmaceuticals GmbH". http://www.ganymed-pharmaceuticals.de/pipeline/imab362.html.
- ↑ "Search of: IMAB362 - List Results - ClinicalTrials.gov". http://clinicaltrials.gov/search/intervention=IMAB362.
- ↑ "Antibody Shines in Advanced Gastric Cancer". 5 June 2016. http://www.medpagetoday.com/MeetingCoverage/ASCO/58317?xid=nl_mpt_DHE_2016-06-06.
 |
